MedTrace Logo

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

NCT01180049 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2019-05-20

Study results available
· View outcomes & findings →

Summary

This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

temsirolimus

175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit

DRUG

temsirolimus

75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2015-11-30
Completion
2018-06-30

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Germany
  • Italy
  • Poland
  • Romania
  • Russia
  • Serbia
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01180049 on ClinicalTrials.gov